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Document your patient's understanding 
of the risks and benefits
When discussing future childbearing with a
woman who has had multiple miscarriages, there
are several important issues to address. First, ask
what concerns she might have about becoming
pregnant again. Second, ascertain how significant
another pregnancy loss would be to her. Third,
outline the therapeutic options, clearly stating that
they alter loss rates but do not guarantee 
successful delivery. Finally, fully document her
understanding of the risks and benefits, including
the possibility of treatment failure. Remember,
even if the miscarriage rate is reduced from 25% 
to 20% with treatment, should your patient 
miscarry, her miscarriage rate is 100%!
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Progesterone produces a small but significant
decrease in miscarriage among pregnant women
with 3 or more unexplained pregnancy losses
(strength of recommendation [SOR]: A, based on a
meta-analysis of 3 small randomized controlled 
trials [RCTs] with wide confidence intervals).
Human chorionic gonadotropin (HCG) reduces the
rate of recurrent pregnancy loss among women
with 2 or more unexplained pregnancy losses
(SOR: B, based on a meta-analysis of 4 RCTs with
significant methodologic weaknesses).
Four types of immunotherapy are ineffective
for preventing miscarriage (SOR: A, based on RCTs
and systematic reviews of RCTs). Aspirin therapy 
is ineffective for preventing recurrent miscarriage
for women who do not have an autoimmune 
explanation for previous pregnancy losses (SOR: A,
based on RCTs).
C L I N I C A L C O M M E N T A R Y
■ Evidence summary
Progesterone. A Cochrane meta-analysis on
the use of progesterone to prevent pregnan-
cy loss looked at a subset of 3 small 
RCTs that evaluated women with 3 or more
pregnancy losses. Patients with primary
recurrent spontaneous abortion (RSA) (no
prior live births), were not differentiated
from those with secondary RSA (previous
live birth with subsequent miscarriages). 
Progesterone administration resulted 
in a significant reduction in miscarriage
compared with placebo (odds ratio
[OR]=0.37; 95% confidence interval [CI],
0.17–0.91), independent of administration
routes (oral, vaginal, or intramuscular).
This benefit was lost in the larger meta-
analysis when studies containing women
with fewer than 3 pregnancy losses were
included.1
Human choriogonadotropin. A meta-
analysis reviewed 4 trials (n=180 total) of
varying methodological quality, which were
constructed to determine if women, with 
at least 2 consecutive miscarriages of
unknown cause, derive any protective effect
when they receive HCG during the first
trimester. Although the overall outcome
favored the use of HCG (OR=0.26 com-
pared with placebo; 95% CI, 0.14–0.52),
the trials contained major methodological
weaknesses (poor description of methods,
no power calculations, selection and unclear
randomization techniques).2
Immunotherapy. A systematic review
of 22 RCTs evaluating 4 different types of
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immunotherapy for recurrent miscarriage
found no significant improvement in live
birth rates. All studies were of high quali-
ty with a low level of bias. Only one
lacked double-blinding. 
Immunotherapy types included: 
paternal leukocyte immunization (PLI)
(11 trials, 596 women) (OR=1.05; 95%
CI, 0.75–1.47); intravenous immune 
globulin (IVIG) (OR=0.98; 95% CI,
0.61–1.58); third-party donor cell immu-
nization (3 trials, 156 women) (OR=1.39;
95% CI, 0.68–2.82); and trophoblast
membrane infusion (1 trial, 37 women)
(OR=0.40; 95% CI, 0.11–1.45).3
A subsequent RCT comparing PLI
with placebo among 79 women with pri-
mary RSA of unknown cause again found
no significant difference in live birth rates
(89% vs 71%, respectively).4 However, an
additional RCT evaluating PLI (32
patients) vs placebo (19 patients) among
women with unexplained primary RSA
did find significantly higher birth rates
with PLI (84% vs 25%; P=.001). This
small study used different techniques than
previous PLI studies.5
A later meta-analysis of 5 RCTs includ-
ing a total of 246 patients also found that
IVIG did not improve the subsequent live
birth rate for women with a history of 
primary or secondary RSA (OR=0.98;
95% CI, 0.45–2.13).6
Aspirin. An RCT involving 54 preg-
nant women (mean age 32.7 years) with a
history of primary RSA of unknown
cause (negative standard workup) evalu-
ated 50 mg of aspirin daily (n=27) vs
placebo (n=27).7 The method of blinding
was not reported. 
The live birth rate was identical for
the 2 groups (88%). A second (unblind-
ed) trial randomized 805 women from a
large referral center (mean age 34 years)
with a history of first-trimester RSA (not
differentiated between primary and sec-
ondary RSA) of unknown cause to either
75 mg of aspirin daily or no treatment.8
There was no significant difference in the
live birth rate between those who took
aspirin (251/367; 68.4%) and those who
did not (278/438; 63.5%; OR=1.24; 
95% CI, 0.93–1.67).
Recommendations from others
The American College of Obstetricians
and Gynecologists (ACOG) states that “it
has not been shown conclusively that
progesterone treatment or corpus luteum
support (HCG) influences pregnancy 
outcome for women with recurrent spon-
taneous abortion.”9 ACOG does not 
recommend immunotherapy, citing a lack
of demonstrated efficacy (IVIG and PLI), a
lack of standards for cell storage and
administration, and a risk profile similar to
that of blood transfusion (PLI). They 
recommend “couples with otherwise unex-
plained recurrent pregnancy loss should be
counseled regarding the potential for 
successful pregnancy without treatment.”
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